Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: Studies in vitro and in diabetic patients

被引:84
作者
Fuhrman, Bianca [1 ]
Volkova, Nina
Aviram, Michael
机构
[1] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Rambam Med Ctr, Lipid Res Lab, IL-31096 Haifa, Israel
关键词
High-density lipoprotein; Paraoxonase-1; Pomegranate juice; Polyphenols; Vitamin E; Oxidative stress; MACROPHAGE CHOLESTEROL EFFLUX; SERUM PARAOXONASE; OXIDATIVE STRESS; LDL OXIDATION; ATHEROSCLEROSIS DEVELOPMENT; ANTIOXIDANT ACTIVITY; PON1; HDL; STIMULATION; CONSUMPTION;
D O I
10.1016/j.nut.2009.05.003
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Objective: The high-density lipoprotein (HDL)-associated paraoxonase-1 (PON1)/free PON1 ratio is lower in diabetic patients in comparison with healthy controls Because diabetes Is associated with increased oxidative stress, we hypothesized that a labeled recombinant PON1 (rePON1) would detect differences in HDL capacity to bind PON1 under specific experimental conditions, such as oxidation, addition of polyphenols, or in vivo closing of diabetic patients with polyphenols. Methods: In the present study we determined labeled rePON1 binding to HDL under various oxidative conditions by using polyacrylamide gel electrophoresis for the separation of free labeled rePON1 from HDL-bound labeled rePON1 Results: The HDL-rePON1/free rePON1 ratio gradually decreased as the extent of HDL oxidation increased, and the antioxidants vitamin E or pomegranate juice (PJ) inhibited the redistribution of rePON1. PJ or its purified polyphenols. punicalagin, gallic acid, or ellagic acid, increased rePON1 binding also to non-oxidized HDL. Further, rePON1 associated more efficiently with HDLs isolated from diabetic patients after PJ consumption versus HDLs isolated before PJ consumption Conclusions: We conclude that 1) oxidative stress impairs binding of fluorescein isothiocyanate labeled rePON1 to HDL and 2) PJ polyphenols directly increase the HDL-rePON1 association beyond their antioxidative effect. (C) 2010 Elsevier Inc All rights reserved
引用
收藏
页码:359 / 366
页数:8
相关论文
共 33 条
[1]
Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization [J].
Aharoni, A ;
Gaidukov, L ;
Yagur, S ;
Toker, L ;
Silman, I ;
Tawfik, DS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :482-487
[2]
Aviram M, 2005, HANDB EXP PHARM, V170, P263
[3]
PLASMA-LIPOPROTEIN SEPARATION BY DISCONTINUOUS DENSITY GRADIENT ULTRA-CENTRIFUGATION IN HYPERLIPOPROTEINEMIC PATIENTS [J].
AVIRAM, M .
BIOCHEMICAL MEDICINE, 1983, 30 (01) :111-118
[4]
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences [J].
Aviram, M ;
Rosenblat, M .
CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (04) :393-399
[5]
Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions - PON1 esterase and peroxidase-like activities [J].
Aviram, M ;
Hardak, E ;
Vaya, J ;
Mahmood, S ;
Milo, S ;
Hoffman, A ;
Billicke, S ;
Draganov, D ;
Rosenblat, M .
CIRCULATION, 2000, 101 (21) :2510-2517
[6]
Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development [J].
Aviram, M ;
Rosenblat, M .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (09) :1304-1316
[7]
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R [J].
Aviram, M ;
Billecke, S ;
Sorenson, R ;
Bisgaier, C ;
Newton, R ;
Rosenblat, M ;
Erogul, J ;
Hsu, C ;
Dunlop, C ;
La Du, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) :1617-1624
[8]
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[9]
Aviram M, 2001, METHOD ENZYMOL, V335, P244